Table S1.
Clinical characteristics of neuroblastoma patients involved in the study
| Sample | Age at diagnosis, months | Sex | CGH class | INRG-HR | INRG stage | Biology | Pretreated | Outcome | Survival, months |
| NB2 | 41 | M | 11q- | + | M | Unfavorable | Yes | AWD | 19+ |
| NB11 | 29 | F | 11q- | − | L | Unfavorable | Yes | NED | 210+ |
| NB12 | 31 | M | 11q- | + | M | Unfavorable | Yes | DOC | 6 |
| NB19 | 33 | F | 11q- | + | M | Unfavorable | Yes | NED | 32+ |
| NB43 | 35 | F | 11q- | + | M | Unfavorable | Yes | NED | 31+ |
| NB44 | 27 | M | 11q- | + | M | Unfavorable | Yes | AWD | 32+ |
| NB45 | 55 | F | 11q- | + | M | Unfavorable | Yes | NED | 20+ |
| NB1 | 41 | M | NMA | + | L | Unfavorable | No | DOD | 17 |
| NB6 | 79 | M | NMA | + | L | Unfavorable | Yes | NED | 70+ |
| NB13 | 19 | F | NMA | + | M | Unfavorable | Yes | DOD | 4 |
| NB14 | 14 | F | NMA | + | M | Unfavorable | Yes | DOD | 13 |
| NB39 | 15 | F | NMA | + | M | Unfavorable | Yes | NED | 13+ |
| NB41 | 136 | M | NMA | + | M | Unfavorable | Yes | DOD | 10 |
| NB34 | 30 | M | NMA | + | M | Unfavorable | Yes | DOD | 5 |
| NB37 | 31 | F | NMA | + | M | Unfavorable | Yes | NED | 59+ |
| NB4 | 10 | M | NO | − | MS | Favorable | No | NED | 49+ |
| NB10 | 0 | M | NO | − | MS | Favorable | No | NED | 126+ |
| NB25 | 11 | F | n.a. | − | MS | Favorable | No | NED | 76+ |
| NB8 | 31 | M | NO | − | L | Favorable | No | NED | 140+ |
| NB9 | 0 | M | NO | − | L | Favorable | No | DOC | 0 |
| NB18 | 43 | F | NO | − | L | Favorable | No | NED | 174+ |
| NB20 | 6 | M | 17q+ | − | L | Unfavorable | No | NED | 44+ |
| NB22 | 6 | M | NO | − | L | Favorable | No | NED | 148+ |
| NB26 | 33 | F | OS | − | L | Favorable | No | NED | 153+ |
| NB28 | 25 | F | NO | − | L | Favorable | No | NED | 40+ |
| NB29 | 0 | F | NO | − | L | Favorable | No | NED | 72+ |
| NB30 | 4 | F | NO | − | L | Favorable | No | NED | 71+ |
| NB31 | 13 | F | NO | − | L | Favorable | No | NED | 84+ |
| NB33 | 110 | M | OS | − | L | Favorable | No | NED | 32+ |
| NB36 | 12 | F | OS | − | L | Favorable | No | NED | 131+ |
| NB38 | 13 | M | OS | − | L | Favorable | No | NED | 76+ |
| NB42 | 12 | F | NO | − | L | Favorable | No | NED | 270+ |
Clinical characteristics of neuroblastoma patients involved in the study. Comparative genomic hybridization (CGH) class (3): NMA, MYCN-amplification; n.a., not annotated; NO, numerical only; OS, other structural; 11q, 11q−; 17q, 17q+ without NMA/11q−. INRG–high-risk (HR) (2): HR +, NMA or INRG stage M, age at diagnosis >18 mo. INRG stage (2): L, localized (INSS stage 1, 2, and 3); M, metastatic (INSS stage 4); MS, metastatic special (INSS stage 4S). Outcome: AWD, alive with disease; DOC, dead of complications; DOD, dead of disease; NED, no evidence of disease. Survival months: survival in completed months from diagnosis; +, still alive.